



**The Minister of Health and Population
Resolution No. 539 of 2007
on Approving the Egyptian Guideline
for Good Manufacturing Practices for Pharmaceuticals**

15 NOV 2021

Minister of Health and Population:

After Perusal of:

- Law No. 127 of 1955 regarding the practice of the profession of pharmacy.
- Presidential Decree No. 383 of 1976 establishing the National Organization for Drug Control and Research (NODCAR)
- Presidential Decree No. 398 of 1995 establishing the National Organization for Research and Control of Biologicals (NORCB)
- Presidential Decree No. 243 of 1996 organizing the Ministry of Health and Population.
- Ministerial Decree No. 435 of 2006 regarding the Egyptian Guideline for good manufacturing practices for pharmaceuticals, Serums and Vaccines.

Decided

Article (1) Adoption of the WHO guideline for good manufacturing practices for pharmaceuticals as an Egyptian guideline for good manufacturing practices. All producing companies in the Arab Republic of Egypt shall abide by the amendments developed by the World Health Organization to this guideline in accordance with recent developments in the field of pharmaceutical manufacturing.

Article (2) In the event that the company producing pharmaceuticals or biologicals, or vaccines and serums does not comply with the requirements set forth in the Guideline, the pharmacy inspection at the Ministry of Health and Population shall undertake the following:

- أ) In the case of minor violations according to the definition of violations in the guideline, the violating company shall be given a grace period to make the necessary amendments in accordance with the requirements contained in the guideline, if the required amendments are not fulfilled within that period, the matter shall be presented to the Technical Committee for Drug Control to take the necessary action towards implementing the mentioned amendments.
- ب) In the case of major and critical deficiencies, according to the definition of violations in the guideline, the production line shall be suspended and production shall not be resumed until after complying with the requirements for good manufacturing

contained in the guideline and the approval of the technical committee for drug control.
The technical committee for drug control may recommend canceling the license of the violating production line in the event of a repeat violation, for which a decision shall be issued by the Central Administration of Pharmaceutical Affairs (CAPA).

Article (3) This decision shall be published in the Egyptian Official Gazette and shall be effective as of the day following the date of its publication.

Minister of Health and Population
(signature)
Prof. Dr. Hatem El-Gabaly

Issued on 06.12.2007



CR: 353570
Tax ID: 200-328-697
ISO 9001-2015 Certified



15 NOV 2021

